A/Prof Perkins is an Adjunct Associate Professor in the Centre for Mental Health at Swinburne University, and a Senior Research Fellow in the School of Population and Global Health at the University of Melbourne, as well as being the Co-Executive Director of Psychae Institute and Co-CEO of Psychae Therapeutics, Australian research and drug development organisations aiming to progress innovative psychedelic therapies as registered medical treatments. Daniel also previously worked in government as the Director of the Office of Medicinal Cannabis in the Victorian Department of Health, focused on research, regulation and drug development activities. He has led a range of psychedelics studies including the world’s largest ever study of almost 10,000 ayahuasca drinkers in 50 countries and is presently an investigator on several clinical trials of psychedelic compounds, including an Australian government funded RCT investigating the use of a DMT based drug for depression and alcohol use disorder.